// STATE LEGISLATION TRACKER

Kansas HB 2029: Reconciling multiple amendments to certain statutes.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Signed

State: Kansas
Bill: HB 2029
Session: 2025-2026
Filed: 2025-01-17
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

Kansas HB2029 appears to be a statute-cleanup bill, not a peptide or healthcare access bill. It reconciles conflicting versions of Kansas statutes amended in multiple bills and does not appear to target compounded peptides, off-label prescribing, telehealth, 503A/503B compounding, controlled substances, or prescription monitoring.

Key Points

No direct peptide-access change is apparent from the bill title, subjects, or summary.
No apparent change to compounded peptide prescribing or pharmacy compounding rules.
No apparent telehealth expansion or restriction for peptide care.
No apparent controlled-substance or prescription-monitoring change for peptide users.

What to Watch For

Note The bill is a reconciliation measure, so it may touch many statutes without changing peptide policy directly.

Note One listed statute is in the health chapter, but the available summary does not show a peptide-specific effect.

Note The user-provided status appears outdated; official Kansas sources now show the bill was signed.

Where the Bill Stands

Kansas legislative records show HB2029 passed the process and was signed by the governor, with approval dated April 27, 2026.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws